Nonlinearity detection: Advantages of nonlinear mixed-effects modeling

AAPS pharmSci

Volumn 2, Issue 3, 2000, Pages 114-

  Jonsson, E Niclas ^a   Karlsson, Mats O ^a   Wade, Janet R ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; METHODOLOGY; NONLINEAR SYSTEM; PHARMACOKINETICS; PHARMACOLOGY;

ALGORITHMS; NONLINEAR DYNAMICS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 18044401499     PISSN: None     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/ps020332     Document Type: Article

References (20)

1. 1. TM Ludden 1991 Nonlinear pharmacokinetics. Clinical Implications Clin Pharmacokinet 20 429 446 1:CAS:528:DyaK3MXlt1KitLg%3D 2044328 10.2165/00003088-199120060-00001 Ludden TM. Nonlinear pharmacokinetics. Clinical Implications. Clin Pharmacokinet. 1991 ; 20: 429–446
2. 2. S Dutta Y Matsumoto WF Ebling 1996 Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci 85 232 239 1:CAS:528:DyaK28XjtFOksQ%3D%3D 8683454 10.1021/js950067y Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci. 1996 ; 85232–239.
3. 3. Spigset O. The selective serotonin reuptake inhibitor fluvoxamine. Ume niversity medical dissertations, 1997.
4. 4. GRP Blackledge 1996 High-dose bicalutamide monotherapy for the treatment of prostrate cancer Urology 47 suppl 1A 44 47 1:STN:280:DyaK287kvFOltA%3D%3D 8560678 10.1016/S0090-4295(96)80008-2 Blackledge GRP. High-dose bicalutamide monotherapy for the treatment of prostrate cancer. Urology 1996 ; 47 (suppl 1A): 44–47
5. 5. AJ Sedman JG Wagner 1974 Importance of the use of the appropriate pharmacokinetic model to analyse in vivo enzyme constants J Pharmacokin Biopharm 2 161 173 1:CAS:528:DyaE2MXjvVChsw%3D%3D 10.1007/BF01061506 Sedman AJ, Wagner JG. Importance of the use of the appropriate pharmacokinetic model to analyse in vivo enzyme constants J Pharmacokin Biopharm. 1974 ; 2: 161–173
6. 6. LB Sheiner B Rosenberg VV Marathe 1977 Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J Pharmacokin Biopharm 5 445 479 1:CAS:528:DyaE1cXksVOiuw%3D%3D 10.1007/BF01061728 Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J Pharmacokin Biopharm. 1977 ; 5: 445–479.
7. 7. LB Sheiner SL Beal 1981 Evaluation of methods for estimating population pharmacokinetic parameters. ii. Biexponential model and experimental pharmacokinetic data J Pharmacokin. Biopharm 9 635 651 1:CAS:528:DyaL38Xmt1GksQ%3D%3D 10.1007/BF01061030 Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. ii. Biexponential model and experimental pharmacokinetic data. J Pharmacokin. Biopharm. 1981 ; 9: 635–651.
8. 8. DA Graves I Chang 1990 Application of NONMEM to routine bioavailability data J Pharmacokin Biopharm 18 145 160 1:CAS:528:DyaK3cXltlygurY%3D 10.1007/BF01063557 Graves DA, Chang I. Application of NONMEM to routine bioavailability data. J Pharmacokin Biopharm. 1990 ; 18: 145–160.
9. 9. O Aarons JW Mandema M Danhof 1991 A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat J Pharmacokin Biopharm 19 485 496 1:CAS:528:DyaK38Xht1Sku7g%3D 10.1007/BF01062959 Aarons O, Mandema JW, Danhof M A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat. J Pharmacokin Biopharm. 1991 ; 19: 485–496.
10. 10. Beal SL, Sheiner LB. NONMEM Users Guides. NONMEM Project Group, University of California at San Francisco, 1992.
11. 11. RC Schoemaker AF Cohen 1996 Estimating impossible curves using NONMEM B J Clin Pharmacol 42 283 290 1:CAS:528:DyaK28XlvVGnsb0%3D 10.1046/j.1365-2125.1996.04231.x Schoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. B J Clin Pharmacol. 1996 ; 42: 283–290.
12. 12. Y Hashimoto S Mori N Hama K Nakao H Imura M Yamaguchi M Yasuhara R Hori 1993 Nonlinear mixed effect modelling of the pharmacodynamics of natriuretic peptides in rats J Pharmacokin Biopharm 21 281 297 1:CAS:528:DyaK2cXhsFCrsbc%3D 10.1007/BF01059780 Hashimoto Y, Mori S, Hama N, Nakao K, Imura H, Yamaguchi M, Yasuhara M, Hori R. Nonlinear mixed effect modelling of the pharmacodynamics of natriuretic peptides in rats. J Pharmacokin Biopharm. 1993 ; 21: 281–297.
13. 13. Y Hashimoto A Odani Y Tanigawara M Yasuhara T Okuno R Hori 1994 Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients Biol Pharm Bull 17 323 326 1:STN:280:DyaK2c3msVKquw%3D%3D 8205132 10.1248/bpb.17.323 Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, and Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull. 1994 ; 17: 323–326.
14. 14. Y Hashimoto J Ozaki T Koue A Odani M Yasuhara R Hori 1994 Simulation for the analysis of distorted pharmacodynamic data Pharm Res 11 545 548 1:CAS:528:DyaK2cXivFSksro%3D 8058613 10.1023/A:1018918600265 Hashimoto Y, Ozaki J, Koue T, Odani A, Yasuhara M, Hori R. Simulation for the analysis of distorted pharmacodynamic data. Pharm Res. 1994 ; 11: 545–548.
15. 15. Beal SL, Sheiner LB. NONMEM Users Guide—Part VII. Conditional estimation methods. University of California at San Francisco, November 1992.
16. 16. JH Rodman K Silverstein 1990 Comparison the two stage (TS) and first order (FO) methods for estimation of population parameters in an intensive pharmacokinetic study Clin Pharmacol Ther. 47 151 151 Rodman JH, Silverstein K. Comparison the two stage (TS) and first order (FO) methods for estimation of population parameters in an intensive pharmacokinetic study. Clin Pharmacol Ther. 1990 ; 47: 151.
17. 17. KR Godfrey WR Fitch 1984 The deterministic identifiability of nonlinear pharmacokinetic models J. Pharmacokin Biopharm 12 177 191 1:CAS:528:DyaL2cXmt1ajt7k%3D 10.1007/BF01059277 Godfrey KR, Fitch WR. The deterministic identifiability of nonlinear pharmacokinetic models. J. Pharmacokin Biopharm. 1984 ; 12: 177–191.
18. 18. KR Godfrey WR Fitch 1984 On the identification of Michaelis-Menton elimination parameters from a single dose-response curve J Pharmacokin Biopharm 12 193 221 1:CAS:528:DyaL2cXmt1ajt7Y%3D 10.1007/BF01059278 Godfrey KR, Fitch WR. On the identification of Michaelis-Menton elimination parameters from a single dose-response curve. J Pharmacokin Biopharm. 1984 ; 12: 193–221.
19. 19. KR Godfrey MJ Chapman S Vajda 1994 Identifiability and indistinguishability of nonlinear pharmacokinetic models J Pharmacokin Biopharm 22 229 251 1:CAS:528:DyaK2MXjsVams7c%3D 10.1007/BF02353330 Godfrey KR, Chapman MJ, Vajda S. Identifiability and indistinguishability of nonlinear pharmacokinetic models. J Pharmacokin Biopharm. 1994 ; 22: 229–251.
20. 20. Y Hashimoto T Koue Y Otsuki M Yasuhara R Hori K Inui 1995 Simulation for population analysis of Michaelis-Menton kinetics J Pharmacokin Biopharm 23 205 216 1:CAS:528:DyaK28XhtVyjtbs%3D 10.1007/BF02354272 Hashimoto Y, Koue T, Otsuki Y, Yasuhara M, Hori R, Inui K. Simulation for population analysis of Michaelis-Menton kinetics. J Pharmacokin Biopharm. 1995 ; 23: 205–216.